ClinicalTrials.gg
Not yet recruitingNCT05416840ECLIPSEUpdated Jan 17, 2024

Effects and Safety of Clonidine Patch on Young and Middle-aged Smokers With Mild Hypertension

A Phase 4 interventional study of Clonidine controlled-release patch and Amlodipine in Hypertension, sponsored by Jing Liu. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by Jing Liu · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
234th of 308
92 · median 253
Started
2024
with 29 others
Phase 4
76 of 410
13 open now
Primary completion
2026-11
later than 60 of 147 live
Registered
239th of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 234th largest by planned enrollment of the 308 interventional ones that give a count, is one of 30 that started in 2024, is one of 76 in phase 4, reaches primary completion later than 60 of the 147 other live ones, and was the 239th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 60 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

The optimal antihypertensive treatment strategy in young and middle-aged hypertensive adults remains undefined. Clonidine controlled-release patches administered once a week might have the advantage of convenience. ECLIPSE trial is intended to explore the effect and patient tolerability of clonidine controlled-release patches (one patch per week for a total of 8 weeks) in the treatment of hypertension in young and middle-aged adults, compared with long-acting antihypertensive drug amlodipine. Clonidine patch was demonstrated ameliorating the early withdrawal symptoms during smoking cessation. This trial is also intended to observe its effect on smoking cessation in young and middle-aged male smokers.

Read the detailed description

The young and middle-aged hypertensive population is growing, but the optimal antihypertensive treatment strategy remains undefined. Young and middle-aged adults have poor adherence to antihypertensive medications and are prone to missed doses, and weekly formulations may be potentially advantageous. As a centrally acting antihypertensive agent, clonidine exerts sustained antihypertensive effects by agonizing alpha2-adrenoceptors. Clonidine controlled-release patches have the advantage of convenience in that they are administered once a week through a transdermal controlled-release technique to achieve a smooth and sustained action of clonidine. However, there is a lack of evidence from clinical trials on its efficacy and tolerability in the treatment of hypertension in young and middle-aged people. ECLIPSE trial is intended to explore the effect and patient tolerability of clonidine controlled-release patches (one patch per week for a total of 8 weeks) in the treatment of hypertension in young and middle-aged adults, compared with long-acting antihypertensive drug amlodipine. Clonidine patch was demonstrated ameliorating the early withdrawal symptoms during smoking cessation and recommended by American Cancer Society to help people quit smoking. Therefore, this trial is also intended to observe its effect on smoking cessation in young and middle-aged male smokers at the same time.

03

Conditions studied

  • Hypertension

Keywords

  • clonidine patch, hypertension, smoking
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-60 years old male with mild hypertension (systolic blood pressure (BP) 140-159 mmHg and/or diastolic BP 90-99 mmHg).
  2. History of smoking and a desire to quit.
  3. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. History of cardiopulmonary and vascular disease.
  2. Severe liver or kidney disease.
  3. Night shift workers, drivers, and those who work at height.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Clonidine

    Patients will receive clonidine controlled-release patch (2.5 mg), once a week

    Drug: Clonidine controlled-release patch

  • Active comparator
    Amlodipine

    Patients will receive amlodipine (5 mg), once daily

    Drug: Amlodipine

Interventions

  • DrugClonidine controlled-release patch

    Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks. All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6).

  • Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks. All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6).

06

What researchers measure

Primary outcomes

  1. Change in clinic sitting systolic BP from baseline at 8-week

    The change in clinic sitting systolic BP from baseline at 8-week in clonidine group and amlodipine group are analyzed, and between groups difference is compared.

    Time frame: 8 weeks

Secondary outcomes

  1. Change in systolic BP in 24 hour ambulatory BP monitoring (ABPM) from baseline at 8-week

    The change in systolic BP in 24 hour ambulatory BP monitoring (ABPM) from baseline at 8-week in clonidine group and amlodipine group are analyzed, and between groups differences are compared.

    Time frame: 8 weeks

  2. Between-group differences in smoking cessation rates at 8-week

    Between-group differences in smoking cessation rates at 8-week in clonidine group and amlodipine are compared

    Time frame: 8 weeks

  3. Drug tolerance and adverse effects during 8 weeks of treatment

    Drug tolerance and adverse effects during 8 weeks of treatment, clonidine or amlodipine, are analyzed

    Time frame: 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Nov 2026, 34 months later.

Of 126 non-industry phase 4 interventional studies under Hypertension, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 34 months is close to that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2022
First posted
Jun 13, 2022
StartEst.
Jan 2024
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05416840
Lead sponsor
Jing Liu
Responsible party
Jing Liu (Director of the Department of Hypertension, Peking University People's Hospital) — Sponsor-investigator
First posted
Jun 13, 2022
Start date
Jan 2024 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 17, 2024

Study contacts

Jing Liu, MD
Contact
heartcenter@163.com
01088325457
Jing Liu, MD
study chair · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion